If you run a pharmaceutical or biotech company in Europe or Asia and a U.S. launch is on your 2027 or 2028 plan, you are probably still treating your home-market price and your U.S. price as two separate decisions. Medicare has started to connect them. From January 1, 2027, a new CMS model called GLOBE ties rebates on some clinic-administered drugs to what 19 other wealthy countries pay. The question for your board is which price you set first, and in which country, because that number may now follow you into the United States.
The short answer
The Global Benchmark for Efficient Drug Pricing (GLOBE) Model is a mandatory Medicare Part B model that CMS finalized on September 30, 2026. It launches on January 1, 2027, runs through March 31, 2032, and applies in randomly selected areas covering about 25% of people with Original Medicare. For in-scope drugs, manufacturers owe a rebate when the Medicare payment exceeds an international benchmark built from prices in 19 countries. The final rule is narrow: it covers single-source drugs and biologicals in seven therapeutic categories with more than $100 million in annual Part B spending, excludes orphan-only drugs, plasma-derived products, certain cell and gene therapies and drugs with a negotiated Medicare price, and waives manufacturers taking part in the GENEROUS Medicaid model. CMS now expects about four manufacturers to remain in scope. As of November 18, 2026, two industry lawsuits against the model are pending and no court has blocked it.
What CMS finalized, and when it starts
CMS announced the final GLOBE rule on September 30, 2026. It was published in the Federal Register on October 2, 2026 (91 Fed. Reg. 62936) and takes effect on November 30, 2026, according to Gibson Dunn’s review of the rule. The proposed version came out in December 2025.
The model sits inside the existing Part B drug inflation rebate program. Part B pays for drugs given by clinicians in offices, infusion centers and hospital outpatient departments, so think oncology infusions, immunology biologics and eye injections rather than pharmacy pills. CMS says GLOBE will operate from January 1, 2027 to March 31, 2032, with rebate invoicing and reconciliation continuing until March 31, 2034. Patients in the selected areas may see lower out-of-pocket costs from April 1, 2027. Sidley’s summary explains the gap: the first quarter of 2027 is a voluntary reporting window in which manufacturers can submit international pricing data, and the first performance period begins on April 1, 2027.
GLOBE model timeline
From proposal to the last rebate invoice
- Dec 2025Proposed rule published
- Sep 30, 2026CMS finalizes GLOBE, with new exclusions and a GENEROUS waiver
- Oct 2, 2026Final rule in the Federal Register (91 Fed. Reg. 62936)
- Oct 7, 2026PhRMA sues in federal court in Washington, D.C.
- Nov 6, 2026BIO, Biocom and California Life Sciences sue in the Northern District of California
- Nov 2026Both suits pending; no ruling reported as of November 11
- Nov 30, 2026Final rule takes effect
- Jan 1, 2027Model launches; Q1 voluntary international pricing data window
- Apr 1, 2027First performance period; lower coinsurance for patients in selected areas
- Mar 31, 2032Model ends
- Mar 31, 2034Rebate invoicing and reconciliation close
Sources: CMS, Sep 30, 2026; Gibson Dunn, Oct 14, 2026; Sidley, Oct 5, 2026; MedicalDaily, Nov 11, 2026.
How the international benchmark works
The benchmark draws on 19 reference countries: Australia, Austria, Belgium, Canada, the Czech Republic, Denmark, France, Germany, Ireland, Israel, Italy, Japan, the Netherlands, Norway, South Korea, Spain, Sweden, Switzerland and the United Kingdom. If you sell in Europe or Japan today, your prices are almost certainly in that set.
CMS can build the benchmark two ways. Method I uses commercially available pricing data and takes the lowest country-level price after adjusting for GDP per capita at purchasing power parity. Method II is voluntary: the manufacturer submits its own net prices in the reference countries, and CMS takes a volume-weighted average, again adjusted for GDP. Where both exist, Sidley reports that the benchmark is the greater of Method I plus 2% or Method II plus 5%. Skadden notes that Method I tends to produce the lower benchmark, so a company that stays silent may face a larger rebate than one that reports.
The per-unit rebate is the greater of two figures: the Part B payment amount minus the international benchmark, or the standard Part B inflation rebate. CMS multiplies it by the units billed for patients in the model areas. The final rebate report arrives no later than eight months after the quarter and works as the invoice, with payment due within 30 days. Gibson Dunn notes a civil money penalty of at least 125% of the rebate for late payment.
How a GLOBE rebate is set
Four steps from drug list to invoice
Drug enters scope
CMS publishes the GLOBE drug HCPCS code list. A drug that crosses the $100 million threshold stays in for the rest of the period.
Price from 19 countries
Method I: lowest GDP-adjusted price. Method II: your reported net prices. The greater of Method I +2% or Method II +5% applies.
Rebate calculated
The greater of Medicare payment minus benchmark, or the standard inflation rebate, times units billed in model areas.
Invoice and payment
Final report within eight months of the quarter end; payment due within 30 days.
Sources: Sidley, Oct 5, 2026; Gibson Dunn, Oct 14, 2026.
Who is in scope, and who is not
The final rule is much smaller than the proposal. In-scope products are Part B single-source drugs and sole-source biologicals in seven categories (antigout agents, antineoplastics, blood products and modifiers, central nervous system agents, immunological agents, metabolic bone disease agents and ophthalmic agents) with more than $100 million in Part B spending over a 12-month period. The rule applies only to Original Medicare, so Medicare Advantage and Part D are outside it.
CMS added exclusions after comments: orphan-only drugs, plasma-derived products and certain cell and gene therapies. Drugs with a maximum fair price under Medicare negotiation are out, and so are biosimilars and their reference biologics once a biosimilar reaches the U.S. market. Newly launched products are excluded until CMS has the data to calculate their rebate, which Sidley reads as a delay for new launches. CMS also declined to exclude oncology drugs or products with breakthrough, fast-track or priority-review designations.
GLOBE scope check
Is your Part B product likely to be covered?
In scope
- ✓Single-source drug or sole-source biological paid under Original Medicare Part B
- ✓One of seven categories, including antineoplastics, immunological and ophthalmic agents
- ✓Over $100 million in Part B spending in a 12-month period
- ✓Oncology and breakthrough-designated drugs are not exempt
Out of scope
- ✕Orphan-only drugs, plasma-derived products, certain cell and gene therapies
- ✕Drugs with a negotiated Medicare price (maximum fair price)
- ✕Biosimilars and their reference products once a biosimilar is on the U.S. market
- ✕Manufacturers in the GENEROUS Medicaid model, for each quarter they take part (waiver)
General screening only; the rule text decides. Sources: CMS, Sep 30, 2026; Sidley; Skadden, Oct 5, 2026.
The largest carve-out is the GENEROUS waiver. CMS says it will waive mandatory participation for any quarter in which a manufacturer takes part in GENEROUS, CMS’s Medicaid drug pricing model. With that waiver and the new exclusions, CMS estimates that only four manufacturers of in-scope drugs remain, and its projected annual Part B savings fell from about $2.3 billion in the proposal to about $80 million.
Projected Medicare Part B savings
The final rule kept the mechanism and shrank the reach
CMS impact estimates as reported by Sidley, Oct 5, 2026. Estimates, not results.
Why a narrow model still matters for a non-U.S. drugmaker
Reading the scope list, many European and Asian companies will conclude GLOBE is someone else’s problem, and for most of them it is, today. I would still put it on the agenda of your next U.S. planning meeting, for one reason: GLOBE turns international reference pricing into working Medicare machinery. Benchmarks, country lists, GDP adjustments, quarterly invoices and penalties are now written into federal regulation. Gibson Dunn notes that expanding the model would need further statutory findings and actuarial certification, so it cannot simply be switched on wider overnight. The design work is done, though, and the Part D companion model, GUARD, was still under review at the Office of Management and Budget as of mid-October.
Having built and run a U.S. home care business, I learned to read Medicare pilots as previews. A rule that touches a few companies in its first year tells you where the payer’s thinking is heading, and companies that plan for that direction early tend to spend less adjusting later. Our earlier piece on the RAPID pathway made the same point for devices: Medicare wants to shape your evidence and your economics before launch, and the earlier you engage, the fewer surprises you get.
There is also a direct link to your European pricing. Under Method I, the lowest GDP-adjusted price among 19 countries can set the benchmark. A deep discount you accept in one smaller market to secure reimbursement could, for an in-scope Part B product, become the number Medicare measures you against. Sidley’s advice to manufacturers is to weigh GLOBE in launch planning, including international launch sequencing and pricing.
The legal challenges
PhRMA filed suit on October 7, 2026 in the U.S. District Court for the District of Columbia, arguing that GLOBE exceeds CMS’s statutory authority. On November 6, BIO, Biocom and California Life Sciences filed a second suit in the Northern District of California. As of November 11, no court had ruled in either case and neither suit had stopped the model. Plan for GLOBE to start on schedule, and watch the dockets through December.
A practical checklist for your 2027 plan
- Map every product you sell or plan to sell in the U.S. by benefit. Only Part B, clinician-administered products are exposed to GLOBE.
- For each Part B product, check the seven categories, the $100 million threshold and the exclusions. Note which drugs could cross the threshold during the model’s life, since a drug that enters stays in.
- Build one table of your current and planned net prices in the 19 reference countries, adjusted for GDP per capita. Find your lowest point.
- Decide who owns the Method II question. Reporting your own net prices may raise the benchmark, but it means sharing confidential data with CMS and documenting any gaps.
- Revisit your launch sequence. If a low-price market sits early in the plan, model what that price would mean as a U.S. benchmark before you commit.
- If you have a U.S. licensing partner or distributor, ask who carries the rebate liability and the reporting work in your contract.
- Put the GUARD rule, the two lawsuits and CMS’s quarterly GLOBE drug list on your regulatory watch list.
What this means if you are entering the U.S.
For most companies outside the U.S., GLOBE will not send an invoice in 2027. Its real effect is on sequence. The old habit was to launch where reimbursement came fastest, set a price country by country, and arrive in America last with the highest list price. Medicare is now measuring itself against those other countries through GLOBE in Part B, and a Part D version, GUARD, is under review. The safer order is to set a global price corridor first, then choose launch countries that protect it, then build the U.S. evidence and payer plan around that corridor. If your U.S. entry also involves buying or building a provider business, our article on Medicare’s new enrollment rules covers the compliance side.
Frequently asked questions
When does the Medicare GLOBE model start?
The final rule takes effect on November 30, 2026. The model launches on January 1, 2027, with a voluntary data reporting window in the first quarter, and the first performance period begins on April 1, 2027. It runs through March 31, 2032.
Which countries are in the GLOBE reference basket?
Nineteen: Australia, Austria, Belgium, Canada, the Czech Republic, Denmark, France, Germany, Ireland, Israel, Italy, Japan, the Netherlands, Norway, South Korea, Spain, Sweden, Switzerland and the United Kingdom.
Does GLOBE apply to Part D or Medicare Advantage?
No. GLOBE covers Original Medicare Part B only. The Part D companion model, GUARD, had not been finalized as of mid-October 2026.
Are new drug launches affected by GLOBE?
Not right away. A newly launched Part B drug is excluded until CMS has the data needed to calculate its rebate, and it must also meet the $100 million spending threshold. A successful launch can enter scope later and then stays in for the rest of the model.
Let’s build the bridge together
Shanbridge helps healthcare and life-sciences companies turn U.S. market access into clear executive decisions, from pricing and launch sequencing to payer positioning and the partners who make a launch work. If you want to test your 2027 plan against GLOBE and the wider move toward international reference pricing, start the conversation.
References
- CMS. CMS Finalizes New Mandatory Drug Payment Model to Deliver Lower Drug Prices for Beneficiaries in Original Medicare Part B. Press release, September 30, 2026.
- CMS. Global Benchmark for Efficient Drug Pricing (GLOBE) Model. Model page.
- Federal Register. Global Benchmark for Efficient Drug Pricing Model. Final rule, document 2026-20281, published October 2, 2026.
- Gibson Dunn. The GLOBE Final Rule: A Narrow Model that May Be a Bellwether for Most Favored Nation Pricing. October 14, 2026.
- Sidley. Most Favored Nation Drug Pricing for Medicare Part B Significantly Narrowed in Final Rule. October 5, 2026.
- Skadden. CMS Finalizes the GLOBE Model: A Most-Favored-Nation Drug Payment Framework for Medicare Part B. October 5, 2026.
- MedicalDaily. A second lawsuit challenges Medicare’s GLOBE model. November 11, 2026.
This article is general information about U.S. regulatory and reimbursement developments as of November 18, 2026. It is not legal, regulatory, pricing or tax advice. Model details, litigation and related rules may change; confirm current requirements with CMS and qualified advisors before making decisions.

